OREANDA-NEWS. Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, will announce the financial results for the first half-year 2016 on Tuesday, September 6, 2016, at 7:00 am CET. An Investor Conference Call with Thomas Meier, PhD, CEO of Santhera Pharmaceuticals, will be held on the same day at 5:00 pm CET.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone® is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for Raxone®, Santhera has filed a Marketing Authorization Application (MAA) in the European Union. Santhera develops Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. 

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. The Company disclaims any obligation to update these forward-looking statements.